OptiNose, Inc. OPTN
Set alert
9.60 0.00 0.00%
At close · May 21
9.60 Day range 9.60
52-week range unavailable
- YTD
- +43.71%
- 1 year
- -46.67%
- Open
- 9.60
- Prev close
- 9.60
- Mkt cap
- 63.11M
- Vol
- 811.06K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.60
- High
- 9.60
- Forward P/E
- -4.65
- Beta
- 0.00
- Short ratio
- 6.05
- Inst. own
- 78.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.5921
- 200-d avg
- 0.96682
- 1y target
- 3.00
3M chart
Signals (12)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Apr 9, 2025 | 1 year ago |
| RSI: Overbought | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Mar 19, 2025 | 1 year ago |
| SMA: Bearish | Mar 18, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 5, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
Key statistics
- Market cap
- 63.11M
- Enterprise value
- -9.26M
- Trailing P/E
- 0.00
- Forward P/E
- -4.65
- PEG ratio
- 0.00
- Price / sales
- 0.83
- Price / book
- 0.00
- EPS (TTM)
- -0.29
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -41.16%
- Revenue (TTM)
- 75.67M
- Revenue growth
- 3.10%
- Free cash flow
- 0
- Total cash
- 82.50M
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 150.83M
- Short % of float
- 5.60%
- 50-day average
- 0.5921
- 200-day average
- 0.96682
Analyst view
Consensus: none
Price target (mean) 3.00 -68.8% downside
Now 9.60
- Target (low)
- 1.00
- Target (mean)
- 3.00
- Target (high)
- 5.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.04667.
Financials — quick view
OPTN Revenue — quarterly 18.51M
OPTN Net income — quarterly -22.42M
OPTN EPS — quarterly -1.92
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.05 | 0.00 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.08 | -0.07 | +0.01 | +12.50% |
| Aug 8, 2024 | Jun 1, 2024 | -0.08 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.10 | -0.12 | -0.02 | -20.00% |
| May 14, 2024 | Mar 1, 2024 | -0.10 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.10 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | Lake Street | main | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 18, 2024 | Lake Street | main | Buy | Buy |
About OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- optinose.com
News
- Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
- Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
- Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
- U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
- OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
- OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
- OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
- Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade
- OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
- OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
Your note
Sign in to keep a note on OPTN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KOHLER TERRY | Chief Financial Officer | Stock Award(Grant) | Oct 6, 2024 | 150,000 |
| KRICK ANTHONY J | Officer | Sale | Jul 16, 2024 | 140,758 |
| MAHMOUD RAMY A | Chief Executive Officer | Sale | Dec 16, 2024 | 1,369,900 |
| MARINO MICHAEL F III | Officer | Sale | Dec 16, 2024 | 544,188 |
| MILLER PETER K | Chief Executive Officer | Sale | Jan 12, 2023 | 957,797 |
| SPENCE PAUL JR. | Officer | Stock Award(Grant) | Feb 27, 2024 | 252,675 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.97% | 16,541,849 | 6.92M | Sep 29, 2024 |
| MVM Partners, LLC | 9.68% | 14,605,263 | 6.11M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 9.52% | 14,356,703 | 6.01M | Sep 29, 2024 |
| Great Point Partners LLC | 8.53% | 12,861,136 | 5.38M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 5.49% | 8,287,503 | 3.47M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 3.77% | 5,688,590 | 2.38M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 3.70% | 5,584,329 | 2.34M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.75% | 2,646,505 | 1.11M | Sep 29, 2024 |
| Fidelity Growth Company K6 Fund | 1.25% | 1,887,911 | 789.90K | Oct 30, 2024 |
| MFS New Discovery Fund | 1.20% | 1,816,449 | 760.00K | Aug 30, 2024 |
| Fidelity Series Growth Company Fund | 1.05% | 1,583,367 | 662.48K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.68% | 1,032,248 | 431.89K | Sep 29, 2024 |